title: Nuclear factor-κB activation inhibitor attenuates ischemia reperfusion injury and inhibits Hmgb1 expression.
abstract: OBJECTIVE
  To investigate the effects of nuclear factor-κB activation inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) on cardiac ischemia reperfusion injury in a transplantation model.
  
  
  METHODS
  Hearts of C57BL/6 mice were flushed and stored in cold Bretschneider solution for 8 h and then transplanted into syngeneic recipient. Some mice were administrated intraperitoneally with DHMEQ (8 mg/kg) 1 h before reperfusion. For inhibition of Hmgb1, mice were treated with glycyrrhizin at 250 mg/kg prior to reperfusion.
  
  
  RESULTS
  DHMEQ decreased cardiomyocyte apoptosis and recruitment of neutrophils and macrophages. Troponin T (TnT) production on 24 h after myocardial IR injury was reduced by DHMEQ treatment. Cardiac output at 60 mmHg of afterload pressure was significantly increased in hearts with DHMEQ treatment (IR+DHMEQ: 58.6 ± 5.75 ml/min; IR: 25.9 ± 4.1 ml/min; P < 0.05). Furthermore, DHMEQ suppressed high mobility group protein (Hmgb1) expression. And the Caspase 3 activity, the number of TUNEL-positive cardiomyocytes and infiltrated neutrophil in cardiac allograft were markedly decreased with Hmgb1 inhibitor treatment.
  
  
  CONCLUSIONS
  Nuclear factor-κB activation inhibitor DHMEQ attenuates ischemia reperfusion injury in a cardiac transplantation model and it may be a suitable agent for the protection of the cardiac against ischemia reperfusion injury.
authors.affiliation: Department of Cardiothoracic Surgery, China Pingmei Shenma Medical Group General Hospital, Pingdingshan Kuanggong Road 1#, Henan, China, zhiyongshi11@163.com.
authors.forename: Zhiyong
authors.initials: Z
authors.lastname: Shi
authors.forename: Aimin
authors.initials: A
authors.lastname: Lian
authors.forename: Fuquan
authors.initials: F
authors.lastname: Zhang
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001549:Benzamides / Q000494:pharmacology / Q000627:therapeutic use*; D003512:Cyclohexanones / Q000494:pharmacology / Q000627:therapeutic use*; D019695:Glycyrrhizic Acid / Q000494:pharmacology; D024243:HMGB1 Protein / Q000037:antagonists & inhibitors; D016027:Heart Transplantation; D008297:Male; D008810:Mice, Inbred C57BL; D009206:Myocardium / Q000378:metabolism; D032383:Myocytes, Cardiac / Q000187:drug effects; D016328:NF-kappa B / Q000037:antagonists & inhibitors* / Q000378:metabolism; D020556:Neutrophil Infiltration / Q000187:drug effects; D009195:Peroxidase / Q000378:metabolism; D015427:Reperfusion Injury / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D020107:Troponin T / Q000097:blood
chemical_list: D001549:Benzamides; D003512:Cyclohexanones; D024243:HMGB1 Protein; C582808:HMGB1 protein, mouse; D016328:NF-kappa B; D020107:Troponin T; C464444:dehydroxymethylepoxyquinomicin; D019695:Glycyrrhizic Acid; D009195:Peroxidase